Dr. Reddy's Announces Azacitidine for Injection Approved by FDA

Loading...
Loading...
Dr. Reddy's Laboratories
RDY
announced today that Azacitidine for Injection 100 mg/vial, a bioequivalent generic version of VIDAZA® (azacitidine for injection), is approved by the United States Food & Drug Administration (USFDA) on September 16, 2013. The launch of product in the market is planned in the near-term. The VIDAZA® brand had U.S. sales of approximately $378.5 Million for the most recent twelve months ending July 2013 according to IMS Health. Dr. Reddy's Azacitidine for Injection 100 mg/vial is available in single-use vials. Disclaimer This press release includes forward-looking statements, as defined in
See full press release
Posted In: NewsGuidanceAsset SalesManagementGlobal
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...